Compare TASK & CRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TASK | CRON |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 969.3M | 1.0B |
| IPO Year | 2021 | 2015 |
| Metric | TASK | CRON |
|---|---|---|
| Price | $6.66 | $2.54 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $14.90 | N/A |
| AVG Volume (30 Days) | 671.1K | ★ 882.6K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | N/A |
| EPS | ★ 1.10 | N/A |
| Revenue | N/A | ★ $146,587,000.00 |
| Revenue This Year | $5.95 | $26.34 |
| Revenue Next Year | $6.46 | $15.53 |
| P/E Ratio | $6.07 | ★ N/A |
| Revenue Growth | N/A | ★ 24.63 |
| 52 Week Low | $6.20 | $1.63 |
| 52 Week High | $18.39 | $3.43 |
| Indicator | TASK | CRON |
|---|---|---|
| Relative Strength Index (RSI) | 28.16 | 49.07 |
| Support Level | $6.20 | $2.44 |
| Resistance Level | $11.28 | $2.61 |
| Average True Range (ATR) | 0.41 | 0.09 |
| MACD | -0.23 | 0.01 |
| Stochastic Oscillator | 9.44 | 52.73 |
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to the world-wide Game-changing companies, helping its clients represent, protect and grow their brands. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.